Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$167.9M net income for the year ended September 30, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| October 1, 2024 – September 30, 2025 | $1,662,400,000 | November 19, 2025 | 10-K ↗ |
| October 1, 2023 – September 30, 2024 | $1,509,400,000 | November 19, 2025 | 10-K ↗ |
| October 1, 2022 – September 30, 2023 | $1,436,900,000 | November 19, 2025 | 10-K ↗ |
| October 1, 2021 – September 30, 2022 | $1,519,100,000 | November 19, 2024 | 10-K ↗ |
| October 1, 2020 – September 30, 2021 | $1,325,800,000 | November 17, 2023 | 10-K ↗ |
| October 1, 2019 – September 30, 2020 | $931,800,000 | November 17, 2022 | 10-K ↗ |
| October 1, 2018 – September 30, 2019 | $428,300,000 | November 18, 2021 | 10-K ↗ |
| January 1, 2017 – December 31, 2017 | $114,300,000 | November 21, 2019 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 13, 2026
Response SHA-256: b6ac310e1b86842b778d43405413691cf76ffb4f816284c5bacd660d8f232219
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.